Can Agios Pharmaceuticals cover its short-term obligations?

Its current ratio is 14.19 — current assets exceed current liabilities.

Where does Agios Pharmaceuticals's balance sheet data come from?

Every line is extracted from Agios Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Agios Pharmaceuticals AGIO Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$89.13M+16.9%	$76.25M-13.6%	$88.21M-36.7%	$139.26M-31.4%
Short-term investments	$765.3M-6.4%	$817.46M+18.7%	$688.72M+7.0%	$643.86M-21.2%
Accounts receivable, net	$10.58M+157%	$4.11M+46.2%	$2.81M—	$0-100%
Inventories	$32.92M+19.2%	$27.62M+44.8%	$19.08M+125%	$8.49M—
Raw materials	$88K-1.1%	$89K+74.5%	$51K—	$0—
Work in process	$30.25M+23.4%	$24.51M+39.5%	$17.57M+133%	$7.55M—
Finished goods	$2.58M-14.5%	$3.02M+107%	$1.46M+54.7%	$942K—
Prepaid expenses and other current assets	$44.13M+9.9%	$40.17M+14.7%	$35.02M-10.1%	$38.96M-2.2%
Contract assets	$10.58M+157%	$4.11M+46.2%	$2.81M+27.4%	$2.21M—
Total current assets	$942.05M-2.4%	$965.6M+15.8%	$833.84M+0.1%	$832.77M-21.7%
Property and equipment, net	$10.78M-7.7%	$11.68M-24.1%	$15.38M-33.1%	$22.99M-20.5%
Operating lease right-of-use assets	5.7%-4,287,899,994%	4,287,900,000%-1,153,000,000%	5,440,900,000%-1,072,000,000%	6,512,900,000%-999,500,000%
Other non-current assets	$3.93M-16.8%	$4.72M+16.4%	$4.06M+2.6%	$3.96M+36.4%
Available-for-sale securities	$310.01M-51.4%	$638.32M+2,069%	$29.44M-90.6%	$313.87M+17.8%
Allowance for credit losses	$0—	$0—	$0—	$0—
Total assets	$1.3B-22.0%	$1.66B+77.5%	$937.12M-24.3%	$1.24B-13.8%
Accounts payable	$18.36M+10.3%	$16.64M+70.2%	$9.78M-47.5%	$18.62M+11.5%
Accrued expenses	$27.26M-41.8%	$46.86M+8.6%	$43.17M+42.2%	$30.35M-5.1%
Operating lease liabilities, current	$18.39M+9.6%	$16.78M+11.8%	$15.01M+9.8%	$13.66M+26.2%
Income taxes payable	$0-100%	$871K—	$0—	$0—
Security deposits	——	——	——	——
Total current liabilities	$82.21M+1.3%	$81.16M+19.4%	$67.96M+8.5%	$62.63M+4.7%
Operating lease liabilities, non-current	$21.82M-45.7%	$40.21M-29.4%	$56.99M-20.8%	$72M-16.0%
Operating Lease Liabilities (Total)	$40.21M-29.4%	$56.99M-20.8%	$72M-16.0%	$85.66M-11.2%
Other non-current liabilities	$90K-89.8%	$880K-23.9%	$1.16M-64.7%	$3.28M—
Total liabilities	$104.11M-14.8%	$122.24M-3.1%	$126.1M-8.6%	$137.9M-5.4%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	$75K+2.7%	$73K+1.4%	$72K+1.4%	$71K0.0%
Additional paid-in capital	$2.56B+2.5%	$2.49B+2.4%	$2.44B+2.1%	$2.39B+2.2%
Retained earnings	-$561.71M-277%	-$148.92M+81.9%	-$822.65M-74.8%	-$470.56M-97.1%
Accumulated other comprehensive income (loss)	$2.19M+244%	-$1.52M-244%	-$441K+96.5%	-$12.54M-946%
Treasury stock	$802.49M0.0%	$802.49M0.0%	$802.49M0.0%	$802.49M0.0%
Total stockholders' equity	$1.19B-22.6%	$1.54B+90.0%	$811.02M-26.3%	$1.1B-14.8%
Total liabilities and stockholders' equity	$1.3B-22.0%	$1.66B+77.5%	$937.12M-24.3%	$1.24B-13.8%
Available-for-Sale Debt Securities - Amortized Cost	$1.07B-26.4%	$1.46B+103%	$718.6M-25.9%	$970.27M-10.5%
AFS and Trading Securities - Unrealized Loss Position Fair Value	$136.2M-82.3%	$768.1M+49.6%	$513.5M-40.9%	$868.2M-8.7%
Allowance for Doubtful Accounts	$174K+40.3%	$124K-17.9%	$151K+152%	$60K—
Allowance for Doubtful Accounts Receivable (Current)	$174K+40.3%	$124K-17.9%	$151K+152%	$60K—
Cash, Cash Equivalents, and Marketable Securities	$136.2M-82.3%	$768.1M+49.6%	$513.5M-40.9%	$868.2M-8.7%
Available For Sale Securities Debt Securities Current	$765.3M-6.4%	$817.46M+18.7%	$688.72M+7.0%	$643.86M-21.2%
Cash Cash Equivalents And Short Term Investments	——	——	——	——
Finished goods	$2.58M-14.5%	$3.02M+107%	$1.46M+54.7%	$942K—
Operating Lease Income - 2022 (Lessor)	——	——	——	——
Operating Lease Income - 2025 (Lessor)	——	——	——	——
Operating Lease Receivables (Current)	——	——	——	——
Deferred Tax Assets and Other Non-Current Assets	$3.93M-16.8%	$4.72M+16.4%	$4.06M+2.6%	$3.96M+36.4%
Investments - Amortized Cost Basis	$1.07B-26.4%	$1.46B+103%	$718.6M-25.9%	$970.27M-10.5%
Net Investment in Lease	$30.45M-29.0%	$42.88M-21.2%	$54.41M-16.5%	$65.13M-13.3%
Long-term marketable securities	$310.01M-51.4%	$638.32M+2,069%	$29.44M-90.6%	$313.87M+17.8%
Operating lease right-of-use assets	$30.45M-29.0%	$42.88M-21.2%	$54.41M-16.5%	$65.13M-13.3%
Other non-current assets	$3.93M-16.8%	$4.72M+16.4%	$4.06M+2.6%	$3.96M+36.4%
Operating Lease Income - 2026 (Lessor)	——	——	——	——
Operating Lease Right-of-Use Assets in Other Assets	$30.45M-29.0%	$42.88M-21.2%	$54.41M-16.5%	$65.13M-13.3%
Software and Technology Licenses, Net	$3.93M-16.8%	$4.72M+16.4%	$4.06M+2.6%	$3.96M+36.4%
Accrued Manufacturing Costs	$27.26M-8.9%	$29.94M+28.9%	$23.23M+28.3%	$18.11M-8.6%
Other Commercial Liabilities	$45.46M-3.0%	$46.86M+8.6%	$43.17M+42.2%	$30.35M-5.1%
Commercial Paper Outstanding	——	——	——	——
Accrued Liabilities, Current	$45.46M-3.0%	$46.86M+8.6%	$43.17M+42.2%	$30.35M-5.1%
Compensation and benefits	$27.26M-8.9%	$29.94M+28.9%	$23.23M+28.3%	$18.11M-8.6%
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——
Lease Liability Payments - 2021	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——
Professional Service Fees Payable	$3.61M-16.3%	$4.32M+38.6%	$3.12M+27.9%	$2.44M+4.3%
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——
Total debt	$40.21M-29.4%	$56.99M-20.8%	$72M-16.0%	$85.66M-11.8%
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Accumulated Loss	37-82.6%	213+41.1%	151-41.7%	259-11.9%
AOCI - Available-for-Sale Securities, Net of Tax	$2.19M+244%	-$1.52M-244%	-$441K+96.5%	-$12.54M-946%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	74.7M+1.8%	73.4M+1.7%	72.2M+1.3%	71.3M+1.0%
Convertible Preferred Stock Authorized Shares	25M0.0%	25M0.0%	25M0.0%	25M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—
Additional paid-in capital	$2.56B+2.5%	$2.49B+2.4%	$2.44B+2.1%	$2.39B+2.2%
Treasury Stock, Value	$802.49M0.0%	$802.49M0.0%	$802.49M0.0%	$802.49M0.0%
Investments - Gross Unrealized Losses	$136.2M-82.3%	$768.1M+49.6%	$513.5M-40.9%	$868.2M-8.7%
Number of Exercisable Options	——	——	——	——
Number of Vested and Expected to Vest Options	——	——	——	——
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share-Based Payment Award Options Outstanding - Number	6.1M+4.8%	5.8M+10.8%	5.3M-8.8%	5.8M+20.3%
Unrealized Gains on Investments	$2.25M+157%	$878K-31.7%	$1.29M+1,198%	$99K+2,375%
Unrealized Losses on Investments (Before Tax)	$61K-97.5%	$2.4M+38.8%	$1.73M-86.3%	$12.63M+951%
Weighted Average Exercise Price of Outstanding Options	$39.62-8.9%	$43.48-3.2%	$44.94-7.9%	$48.81-16.6%
Weighted Average Exercise Price of Vested and Expected to Vest Options	——	——	——	——
Components	0—	0—	0—	0—
Cumulative Cost Basis	$1.07B-26.4%	$1.46B+103%	$718.6M-25.9%	$970.27M-10.5%
Operating Lease Income - 2023 (Lessor)	——	——	——	——
Operating Lease Income - 2024 (Lessor)	——	——	——	——
Professional service fees	$3.61M-16.3%	$4.32M+38.6%	$3.12M+27.9%	$2.44M+4.3%
Accrued research and development costs	$12.08M+14.5%	$10.55M-31.8%	$15.46M+83.5%	$8.43M+40.9%
Allowance for doubtful accounts	$174K+40.3%	$124K-17.9%	$151K+152%	$60K—
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$61K-97.5%	$2.4M+38.8%	$1.73M-86.3%	$12.63M+951%
Gross Unrealized Gains	$2.25M+157%	$878K-31.7%	$1.29M+1,198%	$99K+2,375%
Total	$1.07B-26.4%	$1.46B+103%	$718.6M-25.9%	$970.27M-10.5%
Available for sale investments	$1.08B-26.1%	$1.46B+103%	$718.16M-25.0%	$957.73M-11.6%
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$125M0.0%	$125M0.0%	$125M0.0%	$125M0.0%
Common stock, shares issued (in shares)	$74.67M+1.8%	$73.37M+1.7%	$72.16M+1.3%	$71.26M+1.0%
Common Stock, Shares, Outstanding	$58.45M+2.3%	$57.16M+2.2%	$55.95M+1.6%	$55.04M+1.3%
Component of accrued expenses	$2.32M+17.7%	$1.97M+49.3%	$1.32M+85.8%	$711K—
Contract with Customer, Asset, after Allowance for Credit Loss	$10.58M+157%	$4.11M+46.2%	$2.81M+27.4%	$2.21M—
Contract With Customer, Contractual Adjustment Reserve	$182K-28.1%	$253K+62.2%	$156K+140%	$65K—
Contract With Customer, Rebate Reserve	$1.27M-5.9%	$1.35M+24.9%	$1.08M+89.2%	$573K—
Contract With Customer, Right To Recover Product, Reserve	$1.04M+113%	$489K+111%	$232K+74.4%	$133K—
Contract With Customer, Total Allowances And Reserves	$2.5M+19.1%	$2.1M+42.4%	$1.47M+90.9%	$771K—
Debt Securities, Available-for-Sale, Allowance for Credit Loss	$0—	$0—	$0—	$0—
Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions	$0—	$0—	$0—	$0—
Debt Securities, Available-for-Sale, Unrealized Loss Position	$136.2M-82.3%	$768.1M+49.6%	$513.5M-40.9%	$868.2M-8.7%
Lessee Operating Lease Liability Payments Due	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——
Remainder of fiscal 2026	——	——	——	——
Letters of Credit Outstanding, Amount	——	——	——	——
Operating Lease Weighted Average Discount Rate Percent	$0.060.0%	$0.060.0%	$0.060.0%	$0.060.0%
Other accrued liabilities	$2.5M+21.3%	$2.06M+52.0%	$1.36M-2.0%	$1.39M-63.9%
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$25M0.0%	$25M0.0%	$25M0.0%	$25M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$6.11M+4.8%	$5.83M+10.8%	$5.26M-8.8%	$5.77M+20.3%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$39.62-8.9%	$43.48-3.2%	$44.94-7.9%	$48.81-16.6%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——
Treasury stock, shares (in shares)	$16.22M0.0%	$16.22M0.0%	$16.22M0.0%	$16.22M—
Remainder of Fiscal Year 2024	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Agios Pharmaceuticals cover its short-term obligations?: Its current ratio is 14.19 — current assets exceed current liabilities.
Where does Agios Pharmaceuticals's balance sheet data come from?: Every line is extracted from Agios Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.